This is the first trial to show that a MRD-guided approach with treatment beyond MRD negativity has a significant advantage over chemotherapy, both in terms of PFS and OS.
Ibrutinib did not prolong survival vs placebo and is linked with increased susceptibility to bleeding in patients with asymptomatic early-stage chronic lymphocytic leukemia, suggesting that a watch-and-wait approach should continue as the standard for this population.